Perhaps by identifying patients with risk factors for prolonged severe neutropenia (i.e. with multivariate models described herein or elsewhere) [12], methods to preemptively mitigate hematologic toxicity with earlier G-CSF administration or more aggressive CRS management could be advantageous, but these hypotheses require prospective investigation. The gene discussed is CSF3; the disease is neutropenia.